AREV Life Sciences Global Gelecekteki Büyüme

Future kriter kontrolleri 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for AREV Life Sciences Global.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	54.4%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

Jan 02

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak AREV Life Sciences Global yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

CNSX:AREV - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CAD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2022	0	-1	0	0	N/A
6/30/2022	0	-1	0	0	N/A
3/31/2022	0	-1	-1	-1	N/A
12/31/2021	0	-1	-1	-1	N/A
9/30/2021	0	-2	-1	-1	N/A
6/30/2021	0	-2	-1	-1	N/A
3/31/2021	0	-2	-1	-1	N/A
12/31/2020	0	-1	0	0	N/A
9/30/2020	0	-1	0	0	N/A
6/30/2020	0	-1	0	0	N/A
3/31/2020	0	-2	0	0	N/A
12/31/2019	0	-3	0	0	N/A
9/30/2019	0	-10	-1	-1	N/A
6/30/2019	0	-10	-1	-1	N/A
3/31/2019	0	-9	-1	-1	N/A
12/31/2018	N/A	-8	-1	-1	N/A
9/30/2018	N/A	-2	-1	-1	N/A
6/30/2018	N/A	-1	-1	-1	N/A
3/31/2018	N/A	-1	-1	-1	N/A
12/31/2017	N/A	-1	-1	0	N/A
9/30/2017	N/A	-1	0	0	N/A
6/30/2017	N/A	0	0	0	N/A
3/31/2017	N/A	0	0	0	N/A
12/31/2016	N/A	0	0	0	N/A
9/30/2016	N/A	0	0	0	N/A
6/30/2016	N/A	0	N/A	0	N/A
3/31/2016	N/A	0	N/A	0	N/A
12/31/2015	N/A	0	N/A	0	N/A
9/30/2015	N/A	0	N/A	0	N/A
6/30/2015	N/A	0	N/A	0	N/A
3/31/2015	N/A	0	N/A	0	N/A
12/31/2014	N/A	0	N/A	0	N/A
9/30/2014	0	0	N/A	0	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	N/A	0	N/A	0	N/A
12/31/2013	N/A	0	N/A	0	N/A
9/30/2013	0	0	N/A	0	N/A
6/30/2013	0	0	N/A	0	N/A
3/31/2013	N/A	0	N/A	0	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: Insufficient data to determine if AREV's forecast earnings growth is above the savings rate (1.9%).

Kazançlar ve Piyasa: Insufficient data to determine if AREV's earnings are forecast to grow faster than the Canadian market

Yüksek Büyüme Kazançları: Insufficient data to determine if AREV's earnings are expected to grow significantly over the next 3 years.

Gelir ve Pazar: Insufficient data to determine if AREV's revenue is forecast to grow faster than the Canadian market.

Yüksek Büyüme Geliri: Insufficient data to determine if AREV's revenue is forecast to grow faster than 20% per year.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: Insufficient data to determine if AREV's Return on Equity is forecast to be high in 3 years time

AREV Life Sciences Global Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024

No independent directors

No independent directors

No independent directors

AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from Board

No independent directors

Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)

Chairman & CEO recently bought CA$59k worth of stock

No independent directors

AREV Life Sciences Global Corp. Announces Management Changes

Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)

AREV Life Sciences Global Corp. Announces the Appointment of Sateesh Apte to the Scientific Advisory Board

Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)

No independent directors

AREV Life Sciences Global Corporation Appoints Brian V. Elliott to its Board of Directors

AREV Life Sciences Global Corp. Appoints Kevin Phelps as Chief Operating Officer

AREV Life Sciences Global Corp. Appoints Douglas Sorocco to Its Scientific Advisory Committee

AREV Life Sciences Settles Pending Litigation with Harvey

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million.

Chairman & CEO exercised options to buy CA$200k worth of stock.

Chairman & CEO recently sold CA$125k worth of stock

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)

AREV NanoTec Brands Inc. Expands Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based Drugs

AREV NanoTec Brands Inc. announced that it has received CAD 0.67 million in funding

Arev Nanotec Brands Inc. Appoints Chad S. Johnson, Esq. as Special Counsel for Corporate Development

AREV NanoTec Brands Inc. Announces Addition of Kevin J. Phelps to its Board of Directors

AREV NanoTec Brands Inc. Appoints Dr. Jay Noller to its Scientific Advisory Board

AREV’s Nanotech Initiates Early-Stage Antiviral Photochemistry Derivation Discovery Program for Pandemic Viral Pathogens

New 90-day high: CA$0.42

AREV Appoints Dr. Roscoe Moore to Join the Advisory Board

AREV NanoTec Brands Inc. Corporate Update on Latest Innovation

AREV NanoTec Brands Inc. Appoints Dr. Uma V. A. Dhanabalan as Advisory Board

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.725 million in funding

AREV NanoTec Brands Inc. announced that it has received CAD 0.1 million in funding from Chiron Partners LLC

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

New 90-day high: CA$0.22

Chairman & CEO recently sold CA$261k worth of stock

AREV NanoTec Brands Inc. Receives Its First Trial Run of Its Naturvac Immune Boost

AREV NanoTec Brands Inc. Appoints Don Shaxon to the Position of VP Marketing

First half earnings released

AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California.

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.16 million in funding

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin